Investors who closely watch the healthcare sector are keeping an eye on Moderna (NASDAQ:MRNA) as its shares are up 12% over ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

Bourse closes higher; oil continues to climb; China halts oil exports; iron ore nears $US100; CSL to supply Canada with vaccines; BHP, Woodside trade ex-dividend. Follow live.

Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used ...

What's changed, and what hasn't, since President Donald Trump declared the U.S. emergency on March 13, 2020. At the time, nearly 2,000 Americans were infected with the virus. But at-home covid tests ...

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 ...

The FDA has approved GSK's Arexvy for adults aged 18 to 49 who have increased risk of complications from the virus.

Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and ...

Creating more hospital beds and boosting immunisation will be key features of a $140 million "winter strategy" aimed at avoiding a repeat of WA's worst-ever flu season. Premier Roger Cook said the ...